Polycation-based nanoparticles for RNAi-mediated cancer treatment

Area of Science:

• Oncology
• Nanotechnology
• Molecular Biology

Background:

• Cancer incidence is rising globally, driven by aging populations and significant socio-economic impact.
• Gene expression deregulation is a hallmark of cancer development.
• RNA interference (RNAi) pathway, modulated by microRNAs and small interfering RNAs (siRNAs), presents a novel therapeutic avenue.

Purpose of the Study:

• To review pre-clinical and clinical studies on polycation-based nanoparticles (polyplexes) for RNAi-mediated anti-cancer interventions.
• To highlight potential RNAi targets and discuss the enhanced permeability and retention (EPR) effect in systemic delivery.
• To assess the clinical translation potential of polyplex-based RNAi therapeutics.

Main Methods:

• Review of pre-clinical and clinical studies involving polycation-based nanocarriers for RNAi delivery.
• Analysis of intratumoural and intravenous administration routes.
• Focus on nanoparticle design for overcoming biological barriers and leveraging the EPR effect.

Main Results:

• Polycation-based nanoparticles (polyplexes) demonstrate versatility in overcoming extracellular and intracellular barriers for RNAi delivery.
• The enhanced permeability and retention (EPR) effect is a key factor in systemic delivery of RNAi therapeutics.
• A cyclodextrin polymer-based nanocarrier system is currently in clinical trials, indicating progress.

Conclusions:

• RNAi therapeutics, delivered via polyplexes, represent a potentially more effective and safer anti-cancer strategy.
• Personalized cancer treatment may be achievable through microRNA-based tumor profiling combined with targeted RNAi.
• Clinical translation of polyplex-based RNAi therapies is progressing, with promising results from ongoing trials.